The origins of cancer cell dormancy. (June 2022)

• Record Type: Journal Article
• Authors: Morales-Valencia, Jorge; David, Gregory
• Is Part Of: Current opinion in genetics & development. Volume 74(2022)
• Publication Date: 2022-06
• Subjects: Genetics -- Periodicals; Developmental biology -- Periodicals; Developmental genetics -- Periodicals; 576.5
• DOI: 10.1016/j.gde.2022.101914
• Languages: English
• ISSNs: 0959-437X

Abstract

Abstract : Cancer cell dormancy has emerged as an important nongenetic driver of drug resistance. Dormant cells are characterized by a reversible cell cycle exit. They represent a reservoir for eventual cancer relapse, and upon reactivation, can fuel metastatic disease. Although dormant cells were originally believed to emerge from a drug-resistant pre-existing cancer subpopulation, this notion has been recently challenged. Here, we review recent evidence indicating that dormancy represents an adaptive strategy employed by cancer cells to avoid the cytotoxic effects of antitumor therapy. Furthermore, we outline the molecular pathways engaged by cancer cells to enter dormancy upon drug exposure, with a focus on cellular senescence as a driver of dormancy.